Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

Stefan Djordjevic, Delphine Lebon, Raphael Itzykson, Hakim Ouled-Haddou, Guillaume Jedraszak, Juliette Harbonnier, Louison Collet, Etienne Paubelle, Nicolas Duployez, Jean Pierre Marolleau, Loïc Garçon, Thomas Boyer

Blood (2023) 142 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2023-179276

Published: 2023

Journal Articles

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study

Juliette Lambert, Emmanuel Raffoux, Delphine Lebon, Thorsten Braun, Mael Heiblig, Alberto Santagostino, Karin Gogat-Marchant, Cécile Pautas

Blood (2023) 142 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2023-179575

Published: 2023

Journal Articles

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Hélène Kemp, Laurène Fenwarth, Delphine Lebon, Nicolas Duployez, Etienne Paubelle, Magalie Joris, Amandine Charbonnier, Lydia Montes, Claude Preudhomme, Christophe Tribouilloy, Jean Pierre Marolleau, Pierre Morel

Blood (2023) 142 (Supplement 1): 3815.

https://doi.org/10.1182/blood-2023-190177

Published: 2023

Journal Articles

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Herve Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Lamya Haddaoui, Raphael Itzykson, Christian Recher, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

Blood (2023) 142 (Supplement 1): 976.

https://doi.org/10.1182/blood-2023-182018

Published: 2023

Journal Articles

Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program

Flore Sicre De Fontbrune, Mony Fahd, Édouard Forcade, Suzanne Tavitian, Cécile Moluçon Chabrot, Fiorenza Barraco, Yosr Hicheri, Delphine Lebon, Sébastien Maury, Anne-Lise Menard, Barbara Możejko-Pastewka, Kevin D Wolter, Bruno Valtier, Thierry Leblanc, Regis Peffault De Latour

Blood (2023) 142 (Supplement 1): 1347.

https://doi.org/10.1182/blood-2023-186493

Published: 2023

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

Impact of Residence in an Agricultural Zone on AML Characteristics

Vincent Marmouset, Berengere Gruson, Veronique Harrivel, Céline Berthon, Nicolas Duployez, Claude Preudhomme, Jean Pierre Marolleau, Pierre Morel, Carine Hauspie, Stéphane Morisset, Delphine Lebon

Blood (2023) 142 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2023-173171

Published: 2023

Journal Articles

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Blood (2023) 142 (Supplement 1): 518.

https://doi.org/10.1182/blood-2023-179192

Published: 2023

Journal Articles

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Blood (2023) 142 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2023-189428

Published: 2023

Journal Articles

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Blood (2023) 142 (Supplement 1): 1471.

https://doi.org/10.1182/blood-2023-174446

Published: 2023

Journal Articles

Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial

Florent Malard, Sylvain Thepot, Thomas Cluzeau, Martin Carre, Delphine Lebon, Cyrielle Gasc, Juliette Jouve, Benoit Levast, Emilie Plantamura, Emmanuel Prestat, Antoine Sabourin, Joel Doré, Mohamad Mohty, Christian Recher

Blood (2022) 140 (Supplement 1): 6215–6217.

https://doi.org/10.1182/blood-2022-165938

Published: 2022

Journal Articles

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Laura Simon, Alexis Caulier, Celine Berthon, Thomas Boyer, Véronique Harrivel, Magalie Joris, Amandine Charbonnier, Etienne Paubelle, Isabelle Leduc, Nicolas Duployez, Christophe Roumier, Claude Preudhomme, Stéphane Morisset, Jean-Pierre Marolleau, Delphine Lebon

Blood (2022) 140 (Supplement 1): 3225–3226.

https://doi.org/10.1182/blood-2022-164840

Published: 2022

Journal Articles

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 537–538.

https://doi.org/10.1182/blood-2022-165464

Published: 2022

Journal Articles

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Blood (2022) 140 (Supplement 1): 6303–6305.

https://doi.org/10.1182/blood-2022-163348

Published: 2022

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Blood (2022) 140 (Supplement 1): 276–278.

https://doi.org/10.1182/blood-2022-163340

Published: 2022

Journal Articles

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 1284.

https://doi.org/10.1182/blood-2021-146666

Published: 2021

Journal Articles

Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide for the Treatment of Severe/Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Mohamad Mohty, Didier Blaise, Regis Peffault De Latour, Myriam Labopin, Marie Detrait, Stephane Girault, Anne Huynh, Hélène Labussière-Wallet, Thierry Lamy, Delphine Lebon, Sébastien Maury, Cecile Renard, Kobby Asubonteng, Floriane Delaval, Ibrahim Yakoub-Agha, Jean-Hugues Dalle

Blood (2021) 138 (Supplement 1): 1789.

https://doi.org/10.1182/blood-2021-147302

Published: 2021

Journal Articles

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2021-146681

Published: 2021

Journal Articles

Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML)

Audrey DA Rocha, Alexis Caulier, Magalie Joris, Amandine Charbonnier, Mathieu Sage, Lavinia Merlusca, Lydia Montes, Nicolas Guillaume, Judith Desoutter, Marie-Noëlle Lacassagne, Marine Quint, Thomas Boyer, Véronique Harrivel, Nicolas Duployez, Alice Marceau, Jean-Pierre Marolleau, Delphine Lebon

Blood (2021) 138 (Supplement 1): 2928.

https://doi.org/10.1182/blood-2021-145523

Published: 2021

Journal Articles

Single-Unit Transfusion Is Non Inferior to Double Unit Transfusion in Patients with Hematological Disorders Receiving Allogeneic or Autologous Bone Marrow Transplant or Induction Chemotherapy for Acute Leukemia: The 1versus2 Prospective Multicentric Randomized Clinical Trial

Blood (2021) 138 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2021-148270

Published: 2021

NARROW

Prognostic Value and Functional Consequences of Calcium Signalling in Acute Myeloid Leukaemia

Gemtuzumab Ozogamicin for Patients with Newly Diagnosed CD33 Positive Acute Myeloid Leukemia: Results from a French Retrospective Observational Study

The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy

Clonal Dynamics of FLT3 -ITD Positive Acute Myeloid Leukemia Patients with Relapsed/Refractory Disease Following Intensive Chemotherapy +/- Midostaurin

Atgam Efficacy and Safety in Moderate-to-Very Severe Acquired Aplastic Anemia: Outcome of a Large Multicenter Cohort of 634 Children and Adults from the French Authorization for Temporary Use Surveillance Program

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Impact of Residence in an Agricultural Zone on AML Characteristics

Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report

Mutational Profile and Dynamics of PPM1D -Mutant Clones in the Spectrum of Myeloid Disorders

Impact of Arsenic Trioxide in the Treatment of Higher Risk Acute Promyelocytic Leukemia

Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial

Standard Risk-Assessment of AML Doesn't Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy

Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1 -Mutated Acute Myeloid Leukemia: An ALFA Study

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide for the Treatment of Severe/Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Negative MRD at Day 100 after Allogenic Hematopoietic Stem Cell Transplant (HSCT): The Grail to Reach in Acute Myeloid Leukemia (AML)

Single-Unit Transfusion Is Non Inferior to Double Unit Transfusion in Patients with Hematological Disorders Receiving Allogeneic or Autologous Bone Marrow Transplant or Induction Chemotherapy for Acute Leukemia: The 1versus2 Prospective Multicentric Randomized Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only